\n
\n
\n Date
\n Event
\n Sentiment
\n Move
\n Catalyst
\n
\n
\n
\n
\n
\n May 05
\n
\n
\n Manufacturing update<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +12.0%
\n
\n
\n
\n API manufacturing for stenoparib on track to support pivotal ovarian trial.
\n
\n
\n
\n
\n Apr 27
\n
\n
\n Patent allowance<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +2.2%
\n
\n
\n
\n USPTO Notice of Allowance for Stenoparib DRP companion diagnostic patent.
\n
\n
\n
\n
\n Apr 21
\n
\n
\n Clinical data posters<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +10.4%
\n
\n
\n
\n AACR posters with new ovarian survival and colorectal cancer data for stenoparib.
\n
\n
\n
\n
\n Mar 31
\n
\n
\n Earnings and update<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +4.8%
\n
\n
\n
\n Full-year 2025 results with Fast Track status and $20M debt financing details.
\n
\n
\n
\n
\n Mar 06
\n
\n
\n Debt financing<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +21.6%
\n
\n
\n
\n $20M non-convertible debt to fund Phase 2 trials and pivotal trial preparation.
\n
\n
\n
\n <\/p>\n
Pattern Detected<\/p>\n
Recent news has typically been followed by positive price reactions, especially around financing, manufacturing, and clinical\/patent milestones.<\/p>\n
Recent Company History<\/p>\n
Over the past few months, Allarity has reported several milestones around stenoparib and its DRP\u00ae companion diagnostic. A March 2026 financing of $20 million debt extended runway into mid-2028, and year-end 2025 results highlighted FDA Fast Track status and ongoing Phase 2 work. April 2026 brought new DRP\u00ae patent allowance and AACR data, followed by a May 2026 update on Phase 3-focused manufacturing. Today\u2019s conference presentation fits into this pattern of ongoing clinical and scientific visibility rather than a new pivotal inflection.<\/p>\n
An effective S-3\/A shelf registration was amended on April 24, 2026 to update the auditor consent, with at least one related 424B3 resale prospectus filed. The amendment did not change the prospectus terms.<\/p>\n
\n This announcement highlights Allarity\u2019s participation in a precision medicine conference, where the CEO will discuss stenoparib\u2019s dual PARP\/WNT mechanism, its 414-mRNA DRP\u00ae biomarker, and ongoing Phase 2 trials. It reinforces the company\u2019s focus on biomarker-driven oncology rather than unveiling new clinical data. In context of recent financing, patent, and manufacturing updates, investors may watch for subsequent trial readouts, regulatory interactions, and further validation of the DRP\u00ae approach.
\n <\/p>\n
\n
\n phase 2
\n
\n medical
\n
\n
<\/p>\n
“a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib”<\/p>\n
Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine\u2019s chances of reaching the market, the size of its potential sales, and the company\u2019s valuation.<\/p>\n
<\/p>\n
\n
\n parp
\n
\n medical
\n
\n
<\/p>\n
“dual PARP and WNT pathway inhibitor\u2014today announced that CEO Thomas Jensen”<\/p>\n
PARP is a family of enzymes that help cells detect and repair damaged DNA; think of them as cellular repair crew members that patch small breaks. It matters to investors because medicines called PARP inhibitors can block these enzymes to kill cancer cells or make other treatments work better, so clinical trials, approvals, or setbacks for PARP-targeting drugs can strongly affect the value of companies developing them.<\/p>\n
<\/p>\n
\n
\n wnt pathway
\n
\n medical
\n
\n
<\/p>\n
“dual PARP and WNT pathway inhibitor\u2014today announced that CEO Thomas Jensen”<\/p>\n
A cellular communication system that uses Wnt proteins to tell cells how to grow, divide and specialize during development and tissue repair. Investors should care because drugs or diagnostics that alter this pathway can affect cancer growth, regenerative medicine, and side\u2011effect risk; it\u2019s like a traffic control system for cells where turning signals up or down can change the course of a disease and therefore the commercial value of related therapies.<\/p>\n
<\/p>\n
\n
\n mRNA
\n
\n medical
\n
\n
<\/p>\n
“Stenoparib DRP\u00ae, based on a 414-mRNA gene expression signature, which is designed”<\/p>\n
mRNA, short for messenger ribonucleic acid, is a biological molecule that carries instructions from a cell\u2019s genetic blueprint to make specific proteins \u2014 like a recipe or software code that tells a kitchen or computer what to produce. Investors care because mRNA is used as a flexible drug and vaccine platform that can be developed and scaled faster than many traditional medicines; its commercial prospects, manufacturing needs, regulatory approval path, and patent position can strongly affect a company\u2019s value.<\/p>\n
<\/p>\n
\n
\n oncology
\n
\n medical
\n
\n
<\/p>\n
“Track: OncologyDate: Monday, May 11, 2026Time: 10:20\u201310:40 CEST Mr.”<\/p>\n
Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets\u2014think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.<\/p>\n
<\/p>\n
AI-generated analysis. Not financial advice.<\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n 05\/08\/2026 – 08:45 AM
\n
\n
<\/p>\n
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n
TARPON SPRINGS, Fla., May 8, 2026 \u2013 Allarity Therapeutics, Inc. (\u201cAllarity\u201d or the \u201cCompany\u201d) (NASDAQ: ALLR<\/a>), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)\u2014a differentiated, dual PARP and WNT pathway inhibitor\u2014today announced that CEO Thomas Jensen has been invited to participate as a speaker at Precision Medicine Forum Europe 2026, taking place May 11\u201312, 2026, in Stockholm, Sweden.<\/p>\n Presentation Details:<\/p>\n Event: Precision Medicine Forum Europe 2026 Mr. Jensen will discuss stenoparib\u2019s dual mechanism of action and Allarity\u2019s predictive biomarker, the Stenoparib DRP\u00ae, based on a 414-mRNA gene expression signature, which is designed to identify patients who may be more likely to benefit from stenoparib, as well as the Company\u2019s ongoing Phase 2 trials.<\/p>\n Mr. Jensen will be available for individual meetings during the conference to discuss Allarity\u2019s clinical development strategy and potential business development opportunities.<\/p>\n About Stenoparib\/2X-121 About the Drug Response Predictor \u2013 DRP\u00ae Companion Diagnostic About Allarity Therapeutics Follow Allarity on Social Media Forward-Looking Statements ###<\/p>\n Company Contact: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Presentation Title: Dual Inhibition of PARP and WNT: A Novel Drug-Biomarker Combination in Clinical Trials
Track: Oncology
Date: Monday, May 11, 2026
Time: 10:20\u201310:40 CEST<\/p>\n
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1\/2 and tankyrase 1\/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT\/\u03b2-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib\u2019s unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer, Small Cell Lung Cancer and colorectal cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. Allarity has two ongoing Phase 2 trial protocols for stenoparib in Ovarian Cancer patients. In the first, patients who had had 2+ lines of therapy were enrolled on stenoparib and given drug twice daily. This protocol has been closed to further enrollment but continues for the enrolled patients who are still receiving benefit from stenoparib administration. The updated data from this study were presented at the AACR special conference on advances in Ovarian Cancer in September 2025. Note that, as these data are from an ongoing trial, analyses may change as the study fully matures. An amended protocol designed expressly to capitalize on the emerging clinical experience with stenoparib in platinum resistant patients began enrolling patients in the summer of 2025. This amended protocol enrolls only platinum resistant or platinum-ineligible patients and is intended to support future pivotal development and eventual regulatory review. In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer (SCLC) began enrolling patients in early 2026 and is currently enrolling patients across multiple U.S. Veterans Administration (VA) sites.<\/p>\n
Allarity uses its drug-specific DRP\u00ae\u00a0to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP\u00ae\u00a0platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature.<\/p>\n
Allarity Therapeutics, Inc. (NASDAQ: ALLR<\/a>) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP\/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP\u00ae\u00a0technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com<\/a>.<\/p>\n
LinkedIn: https:\/\/www.linkedin.com\/company\/allaritytx\/<\/p>\n
This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company\u2019s current expectations or forecasts of future events. The words \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwould\u201d and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding Allarity\u2019s CEO\u2019s planned presentation at Precision Medicine Forum Europe 2026, the Company\u2019s ongoing and planned clinical development of stenoparib, the potential clinical relevance of stenoparib\u2019s dual inhibition of PARP and the WNT pathway, the potential utility of the Company\u2019s stenoparib DRP\u00ae predictive biomarker based on a 414-mRNA gene expression signature, and the Company\u2019s ability to pursue business development opportunities. Any forward-looking statements in this press release are based on management\u2019s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the successful delivery of the presentation, interpretation or reception of the information presented, clinical development and regulatory review of stenoparib, the possibility that ongoing or future clinical trials may not support safety, efficacy, durability, or biomarker-related claims, the predictive accuracy, validation, regulatory acceptance, and clinical utility of the stenoparib DRP\u00ae predictive biomarker, and the Company\u2019s ability to secure sufficient funding or partnerships to support its development plans. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled \u201cRisk Factors\u201d in our Form 10-K annual report filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on March 30, 2026, available at the SEC\u2019s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company\u2019s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.<\/p>\n
\u00a0 \u00a0 \u00a0 \u00a0 investorrelations@allarity.com<\/p>\n
Media Contact:
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Thomas Pedersen
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Carrotize PR & Communications
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0+45 6062 9390
\u00a0 \u00a0 \u00a0 \u00a0 tsp@carrotize.com<\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/05\/1778250322_314_ti.gif\"\/)
![\"\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/05\/Allarity-Therapeutics-Inc-.png\")